Molecular genetics of facioscapulohumeral muscular dystrophy

https://doi.org/10.1016/0960-8966(93)90102-PGet rights and content

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder. The disease affects specific muscles of the face, shoulder-girdle and upper arm. The biochemical defect underlying FSHD is unknown and there are no specific tests that are diagnostic of FSHD. Genetic linkage studies have mapped the FSHD gene to chromosome 4q35. A DNA marker (p13E-11; D4F104S1, formerly D4S810) has been isolated which recognizes two highly polymorphic loci detectable by EcoRI or HindIII; one locus maps to chromosome 4q35 and shows fragments between about 50 and 320 kb. In FSHD patients deletions occur within this EcoRI/HindIII fragment, yielding fragments that are usually smaller than 28 kb. Characterization of the polymorphic fragments demonstrates that they consist of a 3.2 kb tandem repeat; their number can range between approximately 12 and 96 within the 4q35-specific fragments. In FSHD patients, an integral number of these tandem repeats are deleted, leaving at maximum eight copies.

References (20)

There are more references available in the full text version of this article.

Cited by (43)

  • Treatment and Management of Muscular Dystrophies

    2021, Neuromuscular Disorders: Treatment and Management
  • DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade

    2019, Developmental Cell
    Citation Excerpt :

    First, DUX4 is a multicopy gene that lies within the D4Z4 macrosatellite repeat array in the subtelomeric region of chromosome 4q (Gabriëls et al., 1999; Lee et al., 1995). The repetitive nature of DUX4’s genomic locus and its highly variable copy number in the human population (Wijmenga et al., 1993) render it difficult to study, possibly hindering its prior identification as a cancer-specific gene. The continued development of experimental and computational techniques for querying repetitive genomic loci may facilitate the identification of additional genes like DUX4 that play unexpected roles in cancer.

  • Genotype and phenotype analysis of 43 Iranian facioscapulohumeral muscular dystrophy patients; Evidence for anticipation

    2018, Neuromuscular Disorders
    Citation Excerpt :

    Healthy individuals carry EcoRI fragments larger than 38 kb (11–110 D4Z4 units), whereas FSHD1 patients carry fragments that are smaller than 35 kb (≤8 D4Z4 units) [5,14]. 9–10 D4Z4 units are considered borderline and have been detected in both normal and affected individuals [3,10,14–18]. Approximately, 10%–30% of FSHD1 cases are caused by de novo mutations and in about half of the de novo cases, with respect to number of repeats observed, there is somatic mosaicism [5,19].

  • A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy

    2016, Neuromuscular Disorders
    Citation Excerpt :

    D4Z4 units were initially considered non-coding DNA regions, having a regulatory role on the formation and/or maintenance of 4q telomeric heterochromatin [55,56]. D4Z4 units have a high content of highly methylated GC-dinucleotides, as well as two dispersed repeat elements (LSau and hhspm3), characteristic of heterochromatic, non-expressed regions of the human genome [57]. The possibility that this region contains a functional gene was largely discounted because DUX4, the only recognizable ORF at each D4Z4 unit, had no evident introns or polyadenylation signals, suggesting that it represented a pseudogene [41].

View all citing articles on Scopus
View full text